

## THE OVERLAP WITH CHRONIC PAIN AND MENTAL HEALTH PHARMACOLOGY

Staff Anesthesiologist / TGH **Director, Pain Services Director, Transitional Pain Program** GoodHope Ehlers Danlos Syndrome Chair in Translational Medicine **Director, GoodHope Ehlers Danlos Syndrome Clinic University Health Network President, Canadian Pain Society** President, Canadian Consortium for the Investigation of Cannabinoids CIHR Chair, Chronic Pain, Mental Health & Substance Use



Twitter Handle: @Drhaclarke

# Centre for Mental Health





### **Presenter Disclosure**

- Faculty: Hance Clarke MD PhD
- Relationships with commercial interests:
  - -Grants/Research Support: Ontario Ministry of Health and Long-Term Care, Avicanna
  - -Speakers Bureau/Honoraria: Master Clinician Alliance
  - -Consulting Fees: n/a
  - –Patents: n/a
  - Other: Managing Life





## **Mitigating Potential Bias**

### • No content in this presentation relates to the previous disclosures





## Outline

1. What is Pain and the current landscape in Canada

2. Understand the overlap in the use of medications for these co-morbid conditions

Provide some pearls and help avoid pitfalls when prescribing 3. medications to the chronic pain patient





## Mechanism of Normal Pain

Pain is the interpretation of what you feel after: Up (transmission) & Down (modulation) & "Processing"





### Nociceptive system

Credit: Dr. Andrew Smith

### Centre for Mental Health TEMERTY FACULTY OF MEDICINE The Experience of Pain UNIVERSITY OF TORONTO Continuing Professional Development



TENS

Credit: Dr. Andrew Smith

## Medications





### Serotonin/Norepinerphrine

### Serotonergic agents

### Central nerves: Ca 2+

Ca 2+ antagonists: Gabapentin



## 1 in 5 North Americans

### Cost to U.S. Canada \$650-700b

Source: Canadian Pain Task Force, CDC

30 million High Impact Pain

### The Burden of Pain in Canada

- Pain affects 1 in 5 Canadians (20%)
  - 7.6M Canadians suffer from chronic pain
  - Disproportionately affects minoritized population
  - Affects quality of life, ability to work and support networks
- Pain cost Canadians upwards of\$40.3B in 2019
  - Represents the largest healthrelated cost in Canada

• Effective management is limited y our poor understanding of ain mechanisms

AN ACTION **PLAN** FOR PAIN IN CANADA



Health Santé Canada Canada



Canadian Pain Task Force,

## The Burden of Pain in Canada

Pain is the number one driver of disability in Canada

- The most common types of disabilities for adults aged 25 to 64 years were pain related (63%), mental health (46%), and flexibility (36%)
- For seniors (65 years or older), pain -related (68%), mobility (63%) and flexibility (59%) we the most common types of disabilities
- Pain is implicated as the culprit for the opioid crisis (i.e. oxycodone / oxycontin)

Pain is a significant driver of Inequity in Health Care and Society

## Further Current Facts

### Budget 2023

- \$192B over 10 years in health transfers to PTs, including \$25B to support common health priorities
- \$2B over 10 years toward the Indigenous Health Equity Fund
- \$359.2M towards the Canadian Drugs and Substances Strategy (incl. \$144M to SUAP)

### Budget 2024

- \$6.1B over six years for a new Canada Disability Benefit
- \$562.5M in 2024-25 towards the Non-Insured Health Benefits Program for First Nations and Inuit populations
- \$630.2M to support Indigenous people's access to mental health services
- \$1.8 billion over five years (with \$748.3 million per year ongoing) to the federal research granting agencies





- Acute pain is a vital, protective mechanism that permits us to live surrounded by potential danger
- Chronic pain is not helpful and is a chronic disease condition (like) diabetes, HBP)
- Chronic pain persists after the normal expected duration of healing (3-6months) and is a brain signal problem, like an alarm that is stuck on
- Senitization: peripheral; central (spinal, including glial cell) component; brain – neuroplasticity with cortical reorganization)
- Surgery and opioids don't work well (medications in general may provide <20% of the overall improvement)
- The internal "harm alarm" is stuck in the "on" posi





### The Brain- Pain Perception



1	Sensory Cortex	Identifies body parts	Physiotherapy
2	Premotor/ motor cortex	Organizes movements	Physiotherapy
3	Cingulate cortex	Concentration and focus	ΟΤ
4	Prefrontal cortex	Problem solving	ΟΤ
5	Hypothalamus/ thalamus	Stress response, regulates autonomic system Psychologist	
6	Amygdala	Fear, anxiety, anticipation, emotion Psychologist	
7	Hippocampus	Memory	
8	Brain stem	Passes messages between the brain and the rest of the body	
			L.

Open Access Full Text Article

PERSPECTIVES

The Toronto General Hospital Transitional Pain Service: development and implementation of a multidisciplinary program to prevent chronic postsurgical pain Katz, Weinrib et al. J Pain Res 2015:8;695-702

onto General Hospital Peter Mus



### Download our TPS How-To Guide

### How-To Guide contains:

- an overview of the TPS approach to patient care
- guidelines regarding assessment of risk factors for Chronic Post-Surgical Pain (CPSP)
- medication management recommendations
- details regarding referral, patient flow, and clinic administration
- information regarding patient evaluation questionnaires and eHealth tools for patients
- details regarding our pain care services including medical and nursing care, psychology, and physiotherapy
- insights regarding the benefits of establishing a TPS and potential challenges when setting up a TPS clinic
- and more!

### Use QR code or Go to: <u>www.transitionalpainservice.ca/establish-tps</u>



### Establishing a Transitional Pain Service

### A Guide for Health Professionals

### Prepared by:

Anna M. Lomanowska Joel Katz Salima S.J. Ladak P. Maxwell Slepian Aliza Z. Weinrib Rita Katznelson Hance Clarke

Transitional Pain Service Toronto General Hospital



### Published June 2021

www.transitionalpainservice.ca



### **Funded by Health Canada Grant**

### www.transitionalpainservice.ca



Santé

Canada

For Patients & Families

For Health Professionals



### Working Together to Relieve Pain



A First-of-Its-Kind Pain Program

Anna Lomanowska PhD





### Leading the Field in Transitional Pain Care

The Transitional Pain Service (TPS) is a comprehensive multidisciplinary pain management program for patients who are at risk for chronic post-surgical pain and disability.

Learn more about the TPS >





## Triad of Pain Treatment





https://www.transitionalpainservice.ca/establish-tps

## Shifting The Focus to Patient Education

### www.transitionalpainservice.ca/learn



### Online Learning Modules Designed for Our Patients

The Transitional Pain Service has developed specialized learning modules to better prepare our patients for treatment at the clinic.

Research studies show that learning more about how pain works helps people better cope and manage their own pain. If you're a person in pain, or you are supporting someone who has ongoing pain, we hope that these resources will be a helpful companion to treatment.

✓ QMedia About Us



Empowering Patients with the Tools to Learn More about our Approach to Pain Treatment



## Module on Chronic Post-Surgical Pain

https://www.transitionalpainservice.ca/learn







## **Module on Psychology Treatment for Pain**

https://www.transitionalpainservice.ca/learn







### In Development: Self-Guided Online Psychology Program



A little kindness can go a long way to ease suffering when living with chronic pain.



This is a mindfulness exercise called the "Kindness and Compassion Meditation". It was first developed by leading mindfulness scholar, Jon Kabat-Zinn.

When you click "Play" below, you will hear guided instructions that will take you through the exercise step by step. Before starting, make sure that you're in a private and quiet space where

Please click "Play" when you're ready. You can also read along with the audio using the

►
6:45







### Managing Pain Before and After Surgery: A course for people undergoing surgery

This is a free self-paced online program designed to help people undergoing surgery and their families better manage pain after surgery and decrease complications.

1:30-2 hours Available for all Canadians

https://www.paincanada.ca/course/managing

## **Common Mental Health Comorbidities**

- Anxiety
- Depression
- Catastrophizing
- Use Disorders

Treating comorbid psychological illnesses such as anxiety and depression will have a positive effect on pain, and on the patient's ability to manage their pain and reduce opioid consumption

Sutherland et al., Progress in Neurpharm 2018

## Chronic Neuropathic Pain Guidelines



### Algorithm for the pharmacological management of neuropathic pain

\*topical lidocaine(second-line for postherpetic neuralgia), methadone, lamotrigine, lacosamide, tapentadol, botulinum toxin

+ limited randomized controlled trial evidence to support add-on combination therapy

Moulin, Boulanger, Clark, Clarke, Dao, Finley et al., Pain Res. & Management Dec, 2014



Consider adding agents sequentially if partial but inadequate pain relief<sup>+</sup>



## Tricyclic Antidepressants

Amitriptyline / Nortriptyline (active metabolite) (25 – 150 mg/d)

TCAs have been shown in small studies to be effective in the treatment of painful diabetic neuropathy (PDN), post-herpetic neuralgia (PHN) and central pain.

• NNT of 5.1 Based on Cochrane Data



Mico et al., 2006; Perahia et al., 2006

## Tricyclic Antidepressants

Fallen out of favour in mood disdorders:

- anticholinergic adverse effects
- adverse cardiac effects (prolonged PR, QRS and QT) intervals as well as orthostatic hypotension)
- Effect take weeks re: mood

 Attenuation of allodynia and hyperalgesia is typically achieved more rapidly





Pacher and Kecskemeti, 2004

## Serotonin and Norepinephrine Reuptake inhibitors

- Indicated for both Major Depressive Disorder and Anxiety Multiple trials demonstrating the efficacy in pain

Duloxetine: strongest evidence is in treating Peripheral Diabetic Neuropathy, fibromyalgia and osteoarthritis.

NNT for a 50% pain reduction in fibromyalgia is 8.

Moulin et al. 2014, *Lunn et al.*, 2014

## Comparing Doses for Pain vs Depression

## Table 1Dosing of antidepressant medications for depression and pain.

Medications	Antidepressant dose
Amitriptyline	100–300 mg daily
Nortriptyline	75–150 mg daily
Duloxetine	60–120 mg daily
Venlafaxine	75–225 mg daily
Desvenlafaxine	50–100 mg daily



Sutherland et al., Progress in Neurpharm 2018

### Pain dose

25–150 mg daily 25–150 mg daily 60 mg daily 37.5–225 mg daily 200–400 mg daily

## Anticonvulsants: Gabapentin and Pregabalin

- Anticonvulsants
- Analgesic
- Alpha 2 delta Ca **Channel blocker**
- Amino Acid substitution more reliable absorption profile than gabapentin.





Clarke H. et al., Anesth Analg.115(2), 428-442, 2012

## How they work:

- Absorption small intestine (Pregabalin substitution more efficient absorption)
- Metabolism & Excretion
- No interactions













## Anticonvulsants: Gabapentin and Pregabalin

- Alcohol withdrawal
- Benzo weaning
- Opioid Weaning
- Use disorders

May be effective in generalized anxiety disorder with comorbid substance use disorder, and social anxiety disorder that does not respond to first line treatments



Attal et al., 2010; Finnerup et al., 2015; Moulin et al., 2014, Coplan et al., 2015

## Anticonvulsants: Gabapentin and Pregabalin

- Post Herpetic Neuralgia
- Painful Diabetic Neuropathy
- Fibromyalgia

\*Minimal efficacy for treating HIV neuropathy

NNT: in the 5.0 PDN and 5.6 range PHN \*Risk of Suicidality in Adolescent patients

Attal et al., 2010; Finnerup et al., 2015; Moulin et al., 2014, Coplan et al., 2015



- Health Canada has reported 40,642 apparent opioid toxicity deaths between Jan  $\bullet$ 2016 & June 2023
- From January to June 2023: 22 deaths / day  $\bullet$
- From January to June 2023: 17 hospitalizations per day total opioid related deaths  $\bullet$ 5% higher than in 2022
- Once COVID started we saw an escalation of suicides in our program  $\bullet$
- Fatal risk doubles from 20 mg to 50 mg daily and 10x if > 90mg (Prescription opioids,  $\bullet$ CDC data)

## **Opioid Crisis and Pain are Intertwined**

### Significant intersections between chronic pain, substance use and the overdose crisis

- **55%** of people who use drugs also live with chronic pain
- 45% of people who died from illegal drug overdose (BC 2018) having sought pain services in the year prior to deaths

Actions to promote appropriate use of opioids led to unintended consequences

- Health professionals reported fear of regulatory scrutiny, inadequate training, insufficient time to manage opioid prescribing for chronic pain.
- People were rapidly tapered or cut off from their opioid medications
- **Increased stigma** for people living with pain



### **Opioid Prescribing Pain Patient Pendulum**



## Problematic Opioid Use

- HIGH RISK lacksquare
  - Multiple street drugs
  - i.v., snort,

- LOW RISK
  - Uses as directed
  - Patient choice to discontinue
  - Complications (sleep apnea, etc)



### MEDIUM RISK Chemical coping Medical diagnosis - overuse



## Mu Opioid Receptor x

- Not a psychiatric medication
- Vulnerable patients can misuse them for their opioid effects
- Mu1 euphoric effects (oxycodone is the winner)
- Mu2 physical dependence

While opioids are effective first-line agents for management of severe, acute pain, their role in management of chronic pain has been called into question because of the side effects and the risk of substance misuse, particularly in patients with psychological disorders.



## Benzodiazepines

Benzodiazepines are not analgesics, but up to one third of patients taking chronic opioids for non-cancer pain have reported concurrent benzodiazepine use and concurrent use of opioids and benzodiazepines is a consistent, strong predictor of problematic opioid use and increased risk of opioid overdose.

 4 trials short term relief of low back pain, less evidence that nonbenzo muscle relaxants



## Cannabis

 A few small studies and many observational trials demonstrating efficacy for cannabis for chronic pain

 2014 Canadian Pain Society Consensus Statement on Chronic Neuropathic Pain suggested using cannabinoids as a third-line agent for management of neuropathic pain

## Canadian Pain Society guidelines

### **CONSENSUS STATEMENT**

### Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society

DE Moulin MD, A Boulanger MD, AJ Clark MD, H Clarke MD PhD, T Dao DMD PhD, GA Finley MD, A Furlan MD PhD, I Gilron MD MSc, A Gordon MD, PK Morley-Forster MD, BJ Sessle MDS PhD, P Squire MD, J Stinson RN PhD, P Taenzer PhD, A Velly DDS PhD, MA Ware MD, EL Weinberg MD, OD Williamson MBBS

"The cannabinoids are analgesic agents with increasing evidence of efficacy in central NeP states, with a combined NNT of 3.4" -2014

Gabapentinoids  $\leftarrow \rightarrow$  TCA  $\leftarrow \rightarrow$  SNRI

### **Recent update moved** cannabinoids from fourth-line to third

Tramadol  $\leftarrow \rightarrow$  Opioid analgesics

Cannabinoids

Consider adding additional agents sequentially if partial but inadequate pain relief

Fourth-line agents



### EUROPEAN PAIN FEDERATION (EFIC) POSITION PAPER ON CANNABIS-BASED MEDICINES FOR CHRONIC PAIN

Medical Condition	EFIC Recommendation
Cancer pain not adequately responding to opioids or other established analgesics	Sativex <sup>®</sup> (nabiximols) as an add-on individu therapeutic trial
Chronic neuropathic pain	Cannabis-based medicine considered for third-line therapy
Chronic non-neuropathic non-cancer pain	Cannabis-based medicine on an individual to basis if patients have failed traditional treatmont Need multidisciplinary assessment of patier

Häuser W et al. European Journal of Pain. 2018;22(9):1547-1564.

	Medical Condition	
al	Cancer pain not adequately responding to opioids or other established analgesics	
	Chronic neuropathic pain	
rial nents. it.	Chronic non-neuropathic non- cancer pain	

## Side effects



1. Kraan T et al., Psych Med 2016. 2. Luzi S et al., Neurotox Res 2008. 3. Lopez-Quntero et al., Drug Alcohol Dep 2011. 4. Fergusson DM et al., Psych Med 2003. 5. Meier MH et al., PNAS 2012.

6. Tashkin DP. Ann Am Thorac Soc 2013. 7. Gordon AJ et al., Curr Psychiatry Rep 2013.

### **Medical Cannabis Real World Evidence** (MC RWE)











Toronto General Toronto Western Princess Margaret Toronto Rehab





### **RWE Clinical Trial**

Adults >19 years of age with a valid medical document

Chronic pain, sleep and anxiety

**Register with Medical Cannabis** by Shoppers



### Assessment using validated scales for pain, sleep, or anxiety PROMIS Pain Interference Short Form 6 and Numerical rating scale



- Pittsburgh Sleep Quality Index
- Generalized Anxiety Disorder-7 scale •
- Patient Health Questionnaire-9 scale (depression) •
- EuroQoL-5D (general health-related quality of life)
- Patient Satisfaction survey



- Total cohort of 266 patients of which 215 reported pain as a primary indication of use
- Mean Age 49.1 ± 16.3 years
- 69% were female
- 39% had chronic pain
- 37% were currently using opioid medications





Yang et al., under review CJP, 2025

### **Outcomes over 6 months**

### Table 2. Cohort outcomes throughout study.

	Pain right now	Pain interference
Time		
Baseline	5.47 (2.38)	22.98 (5.98)
Missing,	n 18	
6 weeks	4.76 (2.57)	19.29 (6.64)
Missing,	n 74	
12 weeks	4.73 (2.51)	19.33 (6.74)
Missing,	n 92	
24 weeks	4.15 (2.56)	18.21 (7.26)
Missing,	n 118	

Values displayed are mean (SD).





Yang et al., under review CJP, 2025







Hance Clarke MD, PhD, FRCPC



Lauren Kelly PhD, MSc, BMedSci, CCRP



**James Mackillop** PhD, CPsych, FCAHS

One in eight Canadian adults use cannabis for medical purposes, but most indications lack high-quality evidence.

The Canadian Medical Cannabis Trials Network will address this knowledge gap by supporting high-quality, rigorous trials of medical cannabis products.

## **Complex Pain Patient Care**





### University Health Network

Toronto General Hospital Toronto Western Hospital Princess Margaret Hospital

## **Opioid Weaning in the Chronic Pain Patient with OUD**

### Journal of Pain Research

Open Access Full Text Article

A case report on the treatment of complex chronic pain and opioid dependence by a multidisciplinary transitional pain service using the ACT Matrix and buprenorphine/naloxone

> This article was published in the following Dove Press journal: Journal of Pain Research 27 March 2017 Number of times this article has been viewed



Weinrib et al. 2017, Journal of Pain Research

**Dove**press open access to scientific and medical research

CASE REPORT

Aliza 7 Weinrib<sup>1,2</sup> Lindsay C Burns<sup>1,2</sup> Alex Mu<sup>1</sup> Muhammad Abid Azam<sup>1,2</sup> Salima SJ Ladak<sup>1</sup> Karen McRae<sup>1,3</sup> Rita Katznelson<sup>1,3</sup> Saam Azargive<sup>1</sup> Cieran Tran<sup>1</sup> oel Katz<sup>1-3</sup> Hance Clarke<sup>1,3</sup>

Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Department of Psychology, York University, <sup>2</sup>Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada



roviders Clinical Support 53



Average pain intensity scores and engagement in meaningful activities over follow-up period.

Notes: Pain was measured using a numeric pain rating scale ranging from 0 (no pain) to 10 (worst pain imaginable). Level of engagement in meaningful activities was assessed from the start of group therapy using a numeric rating scale ranging from 0 (not doing anything that matters) to 10 (doing everything that matters). Single case report.

### Opioid Weaning in a Long-term Opioid Patient



Average pain intensity scores and engagement in meaningful activities over follow-up period.

**Notes:** Pain was measured using a numeric pain rating scale ranging from 0 (no pain) to 10 (worst pain imaginable). Level of engagement in meaningful activities was assessed from the start of group therapy using a numeric rating scale ranging from 0 (not doing anything that matters) to 10 (doing everything that matters). Single case report.

### Remote buprenorphine-naloxone initiation as an essential service for people with chronic pain and opioid dependence during the COVID-19 pandemic: Case reports, clinical pathways, and implications for the future

Hance Clarke<sup>a,b,c</sup>, Aliza Weinrib<sup>b,d</sup>, Yuvaraj Kotteeswaran<sup>a,b</sup>, Joel Katz<sup>a,b,c,d</sup>, Alvis Yu<sup>e,f</sup>, and Robert Tanguay<sup>f,g,h</sup>

<sup>a</sup>Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada; <sup>b</sup>Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; <sup>c</sup>University of Toronto Centre for the Study of Pain, Toronto, Ontario, Canada; <sup>d</sup>Department of Psychology, York University, Toronto, Ontario, Canada; <sup>e</sup>Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada; <sup>f</sup>Opioid Deprescribing Program, Alberta Health Services, Calgary, Alberta, Canada; <sup>g</sup>Department of Psychiatry and Surgery, University of Calgary, Calgary, Alberta, Canada; <sup>h</sup>Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

### ABSTRACT

Many health care professions have reacted swiftly to the COVID-19 pandemic. In-person care has been ramped down and telemedicine/telehealth has been thrust to the forefront of clinical care. For people living with chronic pain and often concomitantly dealing with opioid-related issues, this is a time of great stress. With population-wide movements to shelter in place, people living with pain are more isolated, more stressed, and more vulnerable to mental health concerns like depression and anxiety that can increase pain-related suffering. This article presents two case reports of patients struggling with chronic pain and opioid dependence in which a telemedicine-based buprenorphine-naloxone conversion was chosen as a treatment option by two Canadian programs: The Transitional Pain Service at the Toronto General Hospital in Toronto, Ontario, and The Opioid Deprescribing Program in Calgary, Alberta. Both cases presented highlight the use of telemedicine during the COVID-19 pandemic and suggest that there will be substantial need for these services well beyond the apex of the crisis. A buprenorphine-naloxone home induction protocol is presented and we provide insight into important lessons learned regarding the appropriate selection of patients with chronic pain struggling with opioid use disorder for buprenorphine-naloxone conversion. The provision of health care during the COVID-19 pandemic has rapidly forced practitioners to evolve novel health care practices, and these changes will have long-term implications.



OPEN ACCESS Check for updates

### **ARTICLE HISTORY**

Received 27 April 2020 Revised 23 June 2020 Accepted 25 June 2020

### **KEYWORDS**

chronic pain; suboxone; COVID-19; telemedicine; buprenorphine-naloxone; telepsychology

## Buprenorphine-naloxone Home Induction Protocol



Clarke, Weinrib, Kotteeswaran et al. Canadian Journal of Pain, Sept. 2020

## TPS Psych protocol for buprenorphine-naloxone (Ladak et al.,

- Support all buprenorphine-naloxone inductions
- ~2 sessions prior to initiation
  - Motivational interviewing
  - Psychoeducation
  - Coping planning (DBT skills)
- ~2-3 sessions after initiation
  - Coping support, continued MI

www.transitionalpainservice.ca

### Standards for Managing Pain in Patients with OUD

**Prescribers** are responsible for managing pain in their patients on OAT whenever possible.

**Patients are supported** in finding alternative pain treatments that are financially and geographically accessible and culturally appropriate.

OAT: opioid agonist therapy. Centre for Addiction and Mental Health. Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. Published May 2021. Available at www.camh.ca. Accessed September 6, 2024.





## Clinical Recommendations for Centre for Managing Pain

- Explore non-pharmacological approaches
  - Consider non-opioid medications before adding opioids
  - Osteoarthritis, Back Pain, Muscle Pain
    - If prescribing opioids for acute pain, limit amounts
    - For people on opioid agonist treatments
    - Consider in split doses for severe chronic pain that requires opioids

Consider consulting with a pain specialist if chronic pain develops and persists for months





CANADIAN JOURNAL OF PAIN 2024, VOL. 8, NO. 1, 2337074 https://doi.org/10.1080/24740527.2024.2337074

### An examination of referrals declined for chronic pain care: There is increasing mental health complexity within care-seeking patients with chronic pain over time

Rachael Bosma<sup>a</sup>, Brittany N. Rosenbloom<sup>a</sup>, Emeralda Burke<sup>a</sup>, Christian Aquino<sup>a</sup>, Cara Stanley<sup>a</sup>, Kimberly Coombs<sup>a</sup>, Adriano Nella<sup>a</sup>, Shamalla James<sup>a</sup>, Hance Clarke<sup>b,c</sup>, David Flamer<sup>d</sup>, Anuj Bhatia<sup>a,e,f,g</sup>, John Flannery<sup>h</sup>, Andrew Smith<sup>i</sup>, and Tania Di Renna<sup>a,f</sup>

- Retrospective chart review of all declined referrals at TAPMI in 2018 and 2022 was conducted
- Number of declined referrals due to mental health complexities increased significantly:
  - 2018: 51 (11%)  $\rightarrow$  2022: 180 (18%) ( $\chi^2$ =10.9, p=0.0009) ullet
  - Significant rise in the number of declines due to mental health service requests was also observed (χ<sup>2</sup>=24.53, p<0.00001)

National Landscape: One in four Canadian multidisciplinary pain treatment centre excluded patients if a co-occurring mental health disorder and/or a substance use disorder was present

TAPMI: Toronto Academic Pain Medicine Institute



**∂** OPEN ACCESS

Check for update

CANADIAN JOURNAL OF PAIN 2024, VOL. 8, NO. 1, 2337074 https://doi.org/10.1080/24740527.2024.2337074

### An examination of referrals declined for chronic pain care: There is increasing mental health complexity within care-seeking patients with chronic pain over time

Rachael Bosma<sup>a</sup>, Brittany N. Rosenbloom<sup>a</sup>, Emeralda Burke<sup>a</sup>, Christian Aquino<sup>a</sup>, Cara Stanley<sup>a</sup>, Kimberly Coombs<sup>a</sup>, Adriano Nella<sup>a</sup>, Shamalla James<sup>a</sup>, Hance Clarke<sup>b,c</sup>, David Flamer<sup>d</sup>, Anuj Bhatia<sup>a,e,f,g</sup>, John Flannery<sup>h</sup>, Andrew Smith<sup>i</sup>, and Tania Di Renna<sup>a,f</sup>

- To tackle complexity of patient population, further specialized resources that combine both pain and mental • health care are required
- Patients with co-occurring pain and mental health concerns may require longitudinal care ۲
- In current health care models, such as in Ontario, funding for pain care is based on the number of new referrals • and patients are expected to be discharged within a year (i.e. acute care model)
- The Canadian Pain Task Force has recently acknowledged disparity in health care due to mental health concerns ulletand highlighted equitable access to comprehensive care as a pillar of focus
- Inpatient care models are being attempted to be created at some centres; outpatient models are scarce ۲



## **Building Community Connections**



Toronto Academic Pain Medicine Institute

**TAPMI** 

RAAM Clinics (HCP Website Referral)

HCP: health care professional; RAAM: Rapid Access Addiction Medicine; TAPMI: Toronto Academic Pain Medicine Institute.



## Treating Pain in People With Concurrent Conditions



### Take Home

- Chronic Pain and Mental Health conditions are intertwined
- Specialized training is needed by providers in both clinical  $\bullet$ environments
- Better discourse is often needed when co-managing patients
- Neurobiology and Neurochemistry are at the heart of Chronic Pain and Mental Health treatment

### Percentage of students reporting past year drug use (selected drugs), 1999–2023 OSDUHS (Grades 7–12)









Evidence. Engagement. Impact.



**CO-HOSTED** BY:







### TORONTO CANNABIS AND CANNABINOID RESEARCH CONSORTIUM



One Day \$100 Tickets: Friday May 2<sup>nd</sup>





### The Canadian Pain Society 45th Annual Scientific Meeting May 1 – 4, 2025 Toronto, Canada University of Toronto Campus



Department of Anesthesia & Pain Management



**Full Conference Info** 





## Questions





